MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients

Lu,Huina; Ding,Yi; Dong,Yan; Luo,Xiu; Wang,Xiuqin; Xiu,Bing; Liang,Aibin; Zhang,Wenjun

doi:10.3892/ol.2022.13450

MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients

Authors:
- Huina Lu
- Yi Ding
- Yan Dong
- Xiu Luo
- Xiuqin Wang
- Bing Xiu
- Aibin Liang
- Wenjun Zhang
View Affiliations

Affiliations: Department of Hematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, P.R. China
Published online on: August 5, 2022 https://doi.org/10.3892/ol.2022.13450
Article Number: 330
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the correlation of microRNA (miR)‑181b‑5p expression with treatment response and long‑term prognosis in acute myeloid leukemia (AML) patients. miR‑181b‑5p was detected in the bone marrow of 84 AML patients before therapy. After induction therapy, the patients exhibiting complete remission (CR) were recorded. Next, event‑free survival (EFS) and overall survival (OS) were calculated. miR‑181b‑5p had excellent potential to discriminate AML patients from healthy donors [area under the curve (AUC): 0.922, 95% confidence interval (CI): 0.873‑0.971)]. In addition, miR‑181b‑5p expression was decreased in AML patients with the FLT3‑ITD mutation (P=0.032) or WT1 mutation (P=0.017) when compared to AML patients without these genetic mutations. Meanwhile, miR‑181b‑5p expression was negatively correlated with the National Comprehensive Cancer Network (NCCN) risk classification of AML (P=0.036). Furthermore, miR‑181b‑5p expression was elevated in CR AML patients compared to non‑CR AML patients (P=0.030). Moreover, higher miR‑181b‑5p expression was associated with favorable accumulating EFS (P=0.001) and OS (P=0.024). In addition, higher miR‑181b‑5p expression was independently associated with better EFS (hazard ratio: 0.698, P=0.012). In conclusion, miR‑181b‑5p insufficiency is associated with induction therapy response failure, unfavorable accumulating EFS and OS in AML patients.

View Figures

View References

1	Aquino VM: Acute myelogenous leukemia. Curr Probl Pediatr Adolesc Health Care. 32:50–58. 2002. View Article : Google Scholar : PubMed/NCBI
2	Shipley JL and Butera JN: Acute myelogenous leukemia. Exp Hematol. 37:649–658. 2009. View Article : Google Scholar
3	De Kouchkovsky I and Abdul-Hay M: ‘Acute myeloid leukemia: A comprehensive review and 2016 update’. Blood Cancer J. 6:e4412016. View Article : Google Scholar : PubMed/NCBI
4	Malfuson JV, Konopacki J, Thepenier C, Eddou H, Foissaud V and de Revel T: Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. Ann Hematol. 91:1871–1877. 2012. View Article : Google Scholar
5	Mika T, Ladigan S, Schork K, Turewicz M, Eisenacher M, Schmiegel W, Schroers R and Baraniskin A: Monocytes–neutrophils-ratio as predictive marker for failure of first induction therapy in AML. Blood Cells Mol Dis. 77:103–108. 2019. View Article : Google Scholar : PubMed/NCBI
6	Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yendamuri S and Calin GA: The role of microRNA in human leukemia: A review. Leukemia. 23:1257–1263. 2009. View Article : Google Scholar
8	Lu F, Zhang J, Ji M, Li P, Du Y, Wang H, Zang S, Ma D, Sun X and Ji C: miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 45:383–392. 2014. View Article : Google Scholar
9	Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, et al: Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119:2314–2324. 2012. View Article : Google Scholar : PubMed/NCBI
10	Seipel K, Messerli C, Wiedemann G, Bacher U and Pabst T: MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. Leuk Res. 89:1062962020. View Article : Google Scholar : PubMed/NCBI
11	Saadi MI, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B and Ramzi M: Aberrant expression of the miR-181b/miR-222 after hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Indian J Hematol Blood Transfus. 35:446–450. 2019. View Article : Google Scholar : PubMed/NCBI
12	Xiang L, Li M, Liu Y, Cen J, Chen Z, Zhen X, Xie X, Cao X and Gu W: The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Ann Hematol. 92:1063–1069. 2013. View Article : Google Scholar
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Liu B, Guo Z and Gao W: miR-181b-5p promotes proliferation and inhibits apoptosis of hypertrophic scar fibroblasts through regulating the MEK/ERK/p21 pathway. Exp Ther Med. 17:1537–1544. 2019.PubMed/NCBI
15	Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
16	Su R, Lin HS, Zhang XH, Yin XL, Ning HM, Liu B, Zhai PF, Gong JN, Shen C, Song L, et al: MiR-181 family: Regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 34:3226–3239. 2015. View Article : Google Scholar : PubMed/NCBI
17	Weng H, Lal K, Yang FF and Chen J: The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 208:225–229. 2015. View Article : Google Scholar
18	Soares-Lima SC, Pombo-de-Oliveira MS and Carneiro FRG: The multiple ways Wnt signaling contributes to acute leukemia pathogenesis. J Leukoc Biol. 108:1081–1099. 2020. View Article : Google Scholar
19	Ruan Z, Lu L, Zhang L and Dong M: Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/beta-catenin signaling pathway. Cancer Gene Ther. 28:785–798. 2021. View Article : Google Scholar : PubMed/NCBI
20	Strotbek M, Schmid S, Sanchez-Gonzalez I, Boerries M, Busch H and Olayioye MA: miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. Int J Cancer. 140:2310–2320. 2017. View Article : Google Scholar : PubMed/NCBI
21	Fragoso R, Mao T, Wang S, Schaffert S, Gong X, Yue S, Luong R, Min H, Yashiro-Ohtani Y, Davis M, et al: Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet. 8:e10028552012. View Article : Google Scholar
22	Nepstad I, Hatfield KJ, Gronningsaeter IS and Reikvam H: The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 21:29072020. View Article : Google Scholar
23	Liu Q, Li W, Zhou Y, Jian J, Han S, Liu C, Li W, Zhu X, Ma D, Ji M and Ji C: PRKD2 promotes progression and chemoresistance of AML via regulating notch1 pathway. Onco Targets Ther. 12:10931–10941. 2019. View Article : Google Scholar : PubMed/NCBI
24	Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR and Reilly JT: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 111:190–195. 2000. View Article : Google Scholar
25	Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, Waack K, Creutzig U, Hanenberg H and Reinhardt D: Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019:16091282019. View Article : Google Scholar
26	Larson RA: Micro-RNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia. Chem Biol Interact. 184:21–25. 2010. View Article : Google Scholar
27	Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 358:1919–1928. 2008. View Article : Google Scholar : PubMed/NCBI
28	Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, et al: NCCN guidelines insights: Acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 19:16–27. 2021. View Article : Google Scholar : PubMed/NCBI
29	Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science. 303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI